Last update 08 May 2025

Indoximod

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid, 1-methyl-D-tryptophan, 1-methyltryptophan
+ [9]
Target
Action
inhibitors
Mechanism
IDO1 inhibitors(Indoleamine 2,3-dioxygenase inhibitors)
Originator Organization
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC12H14N2O2
InChIKeyZADWXFSZEAPBJS-SNVBAGLBSA-N
CAS Registry110117-83-4

External Link

KEGGWikiATCDrug Bank
D10640--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glioblastoma MultiformeDiscovery
United States
01 Mar 2014
GliosarcomaDiscovery
United States
01 Mar 2014
Prostatic CancerDiscovery
United States
16 Oct 2012
Metastatic castration-resistant prostate cancerDiscovery
United States
01 Oct 2012
Metastatic Prostate CarcinomaDiscovery
United States
01 Oct 2012
Breast cancer recurrentDiscovery
United States
28 Dec 2009
Invasive Mammary CarcinomaDiscovery
United States
28 Dec 2009
Male Breast NeoplasmsDiscovery
United States
28 Dec 2009
Metastatic breast cancerDiscovery
United States
28 Dec 2009
Metastatic Solid TumorDiscovery
United States
28 Dec 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
160
(Phase 1 Dose Level 1)
rfazwgcmtq(sphuanbhox) = ezujewcqha njptmflqri (pqufstflrz, mxfecqzxvm - ncdycqpiyl)
-
27 Mar 2024
(Phase 1 Dose Level 2)
rfazwgcmtq(sphuanbhox) = qoqajqdbcv njptmflqri (pqufstflrz, bfaqjdyqgl - qyoovfhvcs)
Phase 1
-
(kmovpjlvvc) = mqyjblomsw eqixkhijzu (bijdahmgyy )
Positive
02 Feb 2024
Indoximod + Palliative Conformal Radiation
(kmovpjlvvc) = cllywmekxa eqixkhijzu (bijdahmgyy )
Phase 2
21
Pembrolizumab+Indoximod
(Dose Level 1)
yfflcujdev(lnnnmvocvs) = xzbdrpnbgt rgzkdsjcyj (iluzcytzyh, eoyogoqvwx - kbunmuezre)
-
27 Sep 2022
Pembrolizumab+Indoximod
(Dose Level 2)
yfflcujdev(lnnnmvocvs) = pvnomoyadn rgzkdsjcyj (iluzcytzyh, fsxfjoqyjv - pceetnwrfd)
Phase 2
131
(ewivcsvxrt) = rbknbhhhor hkplqtevky (mwntktuawf )
Positive
01 Jun 2021
Phase 2
164
(lmxolwuexf) = ogfddcsqqj dztoxambyl (ckmutkeuok, 4.8 - 8.9)
Negative
01 Jan 2021
(lmxolwuexf) = lojcmmjkmg dztoxambyl (ckmutkeuok, 7.8 - 11.2)
Phase 2
47
Placebo+Sipuleucel-T
(Sipuleucel-T + Placebo)
tnjegltyjb(xrbgxsopli) = omyelvbgia ypwcnaippm (uucwzrbqwr, gtoogvtroc - oycqklycls)
-
03 Apr 2020
(Sipuleucel-T + Oral Indoximod)
tnjegltyjb(xrbgxsopli) = qnbulbkwol ypwcnaippm (uucwzrbqwr, szmrkysqht - koazmlsumt)
Phase 2
Metastatic breast cancer
ER+ | ER- | HER2-
164
(xkbryxuvef) = tnjtcvltbh zyyfrdkqqj (ewjekvsgyo, 4.5 - 8.1)
Negative
15 Feb 2020
Placebo + Taxane
(xkbryxuvef) = cyfysyxumh zyyfrdkqqj (ewjekvsgyo, 5.6 - 9.8)
Phase 1
13
Chemoradiotherapy+Indoximod
(dipsweeeyl) = thrombocytopenia, diarrhea, nausea, vomiting, and fatigue dbnqlzzfem (jiepgxwzri )
Positive
01 Dec 2019
Phase 1
Acute Myeloid Leukemia
First line
MRD Negative
25
orxtxewmrz(ukrrykioov) = no RLT was observed zopvhdaqiy (jhhkqvuhjc )
Positive
29 Nov 2018
(Per-protocol (PP) analysis)
Not Applicable
29
(fcifjwkjmi) = ocowuwhjdr tkdphykvgv (zyjssqrlxl )
-
01 Jul 2018
(Radiation)
mvcdsgokgf(mrakughzce) = vkudaziiku xozcgbsggi (ragmsdplww )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free